Tysabri Progressive Multifocal Leukoencephalopathy Settlement Criteria

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of General Health and Science Information

The Immunodeficiency Foundation has long served as a repository for scientific and historical records, offering a broad perspective on general health and the evolution of medical knowledge. Its archives document the foundational principles of immunology, tracing how the body’s defenses are understood and managed across diverse contexts. This legacy provides a critical backdrop for examining how therapeutic interventions intersect with patient safety over time. Within this framework, the transition from general health science to specific occupational exposure concerns becomes a natural progression. As medical treatments advance, the environments in which they are administered—and the professionals involved—require careful scrutiny. The shift in focus moves from population-level health information to the precise conditions under which certain therapies are delivered. This pivot acknowledges that the same scientific rigor applied to understanding immune function must now be directed toward the practical realities of clinical and manufacturing settings. Here, the concern centers on exposure to biologic agents, such as those used in monoclonal antibody therapies, and the need to establish clear criteria for monitoring and managing associated risks. The archive’s commitment to preserving knowledge thus extends to documenting the protocols and thresholds that define safe practice in these specialized domains.

Bridge to Tysabri and PML

Building on this foundation of rigorous documentation, we now turn to a specific biologic therapy: Tysabri (natalizumab). Approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease, Tysabri carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following sections synthesize evidence from FDA-approved labeling to describe the clinical presentation, mechanistic links, risk factors, and settlement-related considerations for affected patients.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of the JC virus, which infects oligodendrocytes and causes progressive demyelination. Early symptoms may include cognitive changes, motor weakness, visual disturbances, or speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA boxed warning emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JCV. In clinical trials, PML occurred in three patients who received Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and viral infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

The primary mechanism linking Tysabri to PML is the drug's inhibition of lymphocyte trafficking into the central nervous system. By blocking alpha-4 integrin-mediated adhesion, Tysabri reduces the number of immune cells available to control JCV replication. This creates a permissive environment for viral reactivation and spread within the brain. The risk is further modulated by patient-specific factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are considered when initiating and continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings Regarding Tysabri and PML

The FDA has mandated a boxed warning for Tysabri that clearly states the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three known risk factors: anti-JCV antibody positivity, longer treatment duration, and prior immunosuppressant use. Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers and patients to be enrolled and to undergo regular monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, cases of PML have continued to occur, raising questions about whether the warnings are sufficient to prevent harm.

Settlement-Related Considerations for Affected Patients

Patients who develop PML after Tysabri therapy may pursue legal claims based on inadequate warnings or failure to mitigate risk. Settlement criteria typically consider the presence of anti-JCV antibodies, duration of treatment, and whether the patient had prior immunosuppressant exposure. The timeline between exposure and documented harm is critical: PML can develop months to years after starting Tysabri, and early detection is essential for improving outcomes. The FDA label advises withholding Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For settlement purposes, evidence of delayed diagnosis or failure to monitor may strengthen a claim. Affected individuals should consult legal counsel experienced in pharmaceutical liability to evaluate their specific circumstances.

Timeline Between Exposure and Documented Harm

In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with longer treatment duration, particularly beyond two years. The latency period can vary, and some cases have been reported after shorter exposure. The FDA label emphasizes that risk factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it work?

Tysabri (natalizumab) is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JC virus, increasing the risk of PML.

What are the settlement criteria for Tysabri-related PML?

Settlement criteria typically consider the presence of anti-JCV antibodies, duration of Tysabri treatment, prior immunosuppressant use, and evidence of delayed diagnosis or failure to monitor. Affected individuals should consult legal counsel experienced in pharmaceutical liability.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.